Discovery of sulfonamide–pyrazole γ-secretase inhibitors
摘要:
Utilizing a pharmacophore hypothesis, previously described gamma-secretase inhibiting HTS hits were evolved into novel tricyclic sulfonamide-pyrazoles, with high in vitro potency, good brain penetration, low metabolic stability, and high clearance. (C) 2010 Elsevier Ltd. All rights reserved.
Discovery of sulfonamide–pyrazole γ-secretase inhibitors
摘要:
Utilizing a pharmacophore hypothesis, previously described gamma-secretase inhibiting HTS hits were evolved into novel tricyclic sulfonamide-pyrazoles, with high in vitro potency, good brain penetration, low metabolic stability, and high clearance. (C) 2010 Elsevier Ltd. All rights reserved.
Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase
申请人:Bowers Simeon
公开号:US20080090817A1
公开(公告)日:2008-04-17
The invention provides N-cyclic sulfonamido compounds and salts of Formula I:
wherein A is as described in the specification and R
1
and R
2
combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.